LT2002017A - Torsemide polymorphs - Google Patents

Torsemide polymorphs

Info

Publication number
LT2002017A
LT2002017A LT2002017A LT2002017A LT2002017A LT 2002017 A LT2002017 A LT 2002017A LT 2002017 A LT2002017 A LT 2002017A LT 2002017 A LT2002017 A LT 2002017A LT 2002017 A LT2002017 A LT 2002017A
Authority
LT
Lithuania
Prior art keywords
torsemide
adduct
polymorphs
disclosed
methods
Prior art date
Application number
LT2002017A
Other languages
English (en)
Other versions
LT5004B (lt
Inventor
Judith Aronhime
Marko Kordova
Anchel Schwartz
Ben Zion Dolitzky
David Leonov
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of LT2002017A publication Critical patent/LT2002017A/lt
Publication of LT5004B publication Critical patent/LT5004B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)

Abstract

The present invention is directed to the novel forms of torsemide, designated Form V, amorphous torsemide, Dupont Form 2 solvent adduct, Dupont Form 2 ethanol adduct and Dupont Form 2 isopropanol adduct. Methods for their preparation are also disclosed. The present invention also relates to process for making torsemide modification (I). Pharmaceutical compositions containing the new forms of torsemide and methods of using them are olso disclosed.ą
LT2002017A 1999-08-11 2002-02-11 Torsemido polimorfai LT5004B (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30

Publications (2)

Publication Number Publication Date
LT2002017A true LT2002017A (lt) 2002-11-25
LT5004B LT5004B (lt) 2003-03-25

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002017A LT5004B (lt) 1999-08-11 2002-02-11 Torsemido polimorfai

Country Status (24)

Country Link
US (1) US6465496B1 (lt)
EP (1) EP1207880A4 (lt)
JP (1) JP2003527319A (lt)
KR (1) KR20020025217A (lt)
CN (1) CN1378448A (lt)
AU (1) AU781461C (lt)
BG (1) BG106400A (lt)
CA (1) CA2379322A1 (lt)
CZ (1) CZ2002404A3 (lt)
DE (1) DE00957398T1 (lt)
ES (1) ES2204354T1 (lt)
HK (1) HK1046636A1 (lt)
HR (1) HRP20020120A2 (lt)
HU (1) HUP0204318A3 (lt)
IL (1) IL148031A0 (lt)
LT (1) LT5004B (lt)
MX (1) MXPA02001369A (lt)
NO (1) NO20020622L (lt)
PL (1) PL354262A1 (lt)
SI (1) SI20816A (lt)
SK (1) SK1912002A3 (lt)
TR (1) TR200200353T2 (lt)
WO (1) WO2001010441A1 (lt)
YU (1) YU9502A (lt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200401462T4 (tr) * 2000-02-17 2004-08-23 Teva Pharmaceutical Industries Ltd. Torsemid modifikasyonu II' yi içeren dengeli bir farmasötik formülasyonu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (lt) * 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
US30633A (en) 1860-11-13 Improvement in fire-escapes
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
NZ521852A (en) * 2000-03-20 2004-10-29 Teva Pharma Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
AU781461B2 (en) 2005-05-26
HUP0204318A2 (en) 2003-05-28
SK1912002A3 (en) 2002-07-02
HK1046636A1 (zh) 2003-01-24
EP1207880A4 (en) 2004-09-01
HRP20020120A2 (en) 2003-10-31
TR200200353T2 (tr) 2002-06-21
MXPA02001369A (es) 2005-08-26
AU6902600A (en) 2001-03-05
US6465496B1 (en) 2002-10-15
HUP0204318A3 (en) 2005-03-29
CA2379322A1 (en) 2001-02-15
DE00957398T1 (de) 2004-04-15
NO20020622L (no) 2002-03-14
AU781461C (en) 2006-02-23
YU9502A (sh) 2005-06-10
PL354262A1 (en) 2003-12-29
EP1207880A1 (en) 2002-05-29
WO2001010441A1 (en) 2001-02-15
CN1378448A (zh) 2002-11-06
ES2204354T1 (es) 2004-05-01
KR20020025217A (ko) 2002-04-03
BG106400A (en) 2002-08-30
CZ2002404A3 (cs) 2002-06-12
SI20816A (sl) 2002-08-31
LT5004B (lt) 2003-03-25
JP2003527319A (ja) 2003-09-16
NO20020622D0 (no) 2002-02-08
IL148031A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
LT2002017A (lt) Torsemide polymorphs
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
MY121760A (en) Benzothiazin and benzoxazin derivatives;their preparation and uses
IL127296A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
HUP9601033A3 (en) Benzofurane derivatives, process for their preparation, use of them as intermediate and pharmaceutical compositions containing the compounds
AU1973997A (en) Pentafluorobenzenesulfonamides and analogs
HU9203761D0 (en) Method for producing substituted pyridine derivatives
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
UA35607C2 (uk) Похідні оксазолідинонкарбонової кислоти, спосіб їх одержання, фармацевтична композиція і спосіб її одержання
AU5835400A (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance
AU582235B2 (en) Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs
AU6551198A (en) Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
YU31995A (sh) Benzotiofeni glikopiranozida, postupak za njihovo dobijanje i njihova farmaceutska formulacija
WO1999058490A3 (en) Novel aryl-hydro naphthalenal kanamines
WO2001007418A3 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
BG105923A (en) Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
NO870228D0 (no) Benzimidazolderivater, fremgangsmaate til deres fremstilling og anvendelse av forbindelsene fremstilt ved fremgangsmaaten.
NO20001706L (no) FremgangsmÕte ved biotransformasjonen av colchiconforbindelser til de tilsvarende 3-glykosylderivater
WO2001083423A3 (en) 2,6-diamino-6-methyl-heptanoic acid and derivatives, process for the preparation thereof and use thereof
SI1200417T1 (en) Method for preparing 2-(2-arylmorpholin-2-yl)ethanol derivatives and intermediates
BG104964A (bg) Подобрен метод за получаване на фармацевтично ценни норбензоморфанови производни
AU1314597A (en) Aromatic polycyclic retinoid-type derivatives, method for preparing same, and use thereof for making pharmaceutical and cosmetic compositions
BG105178A (bg) Нови 2,3,3а,4,9,9а-хексахидро-8-хидрокси-1н-бенз/f/индоли, метод за получаването им и приложението им като лекарствени средства